Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive UTA2-1 peptide-loaded PD-L1/L2-silenced donor dendritic cell vaccination after allogeneic stem cell transplantation
NL-OMON45903Not yet recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Dec 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of UTA2-1 peptide-loaded PD-L1/L2-silenced donor dendritic cell vaccine in multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by Vrije University Medical Center. Primary endpoints: Toxicity and feasibility and Immune status and UTA2-1-specific T-cell responses. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
UTA2-1 peptide-loaded PD-L1/L2-silenced donor dendritic cell vaccine
03
Conditions
multiple myeloma (MM)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON45903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45903.